Strain Name:

B6.129S1-Mapk8tm1Flv/J

Stock Number:

004319

Order this mouse

Availability:

Repository- Live

Use Restrictions Apply, see Terms of Use
Mice that are homozygous for the knock-out mutation are susceptible to Leishmania major infection. This mutant mouse strain represents a model that may be useful in studies related to signal transduction.

Description

Strain Information

Former Names B6.129-Mapk8tm1Flv/J    (Changed: 20-DEC-06 )
Type Congenic; Mutant Strain; Targeted Mutation;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Additional information on Congenic nomenclature.
Mating SystemHeterozygote x Heterozygote         (Female x Male)   01-MAR-06
Specieslaboratory mouse
GenerationN5+1N1F5 (24-MAR-11)
Generation Definitions
 
Donating InvestigatorDr. Richard A. Flavell,   Yale University School of Medicine

Description
Mice that are homozygous for the targeted mutation are viable, normal in size, do not display any gross physical or behavioral abnormalities and are fertile but poor breeders. No gene product, protein or mRNA, is detected. Lymphocyte development, T cell to B cell ratio and CD4 to CD8 ratio are normal. Naive Th cells activated in vitro preferentially differentiate into Th2 cells. Mutant mice are susceptible to infection when challenged with the intracellular pathogen, Leishmania major. Primary murine embryonic fibroblasts prepared from mutant embryos are partially protected from UV-induced apoptosis. This mutant mouse strain represents a model that may be useful in studies related to signal transduction.

Development
A targeting vector containing a hygromycin phosphotransferase gene driven by the mouse phosphoglycerate kinase promoter and a herpes simplex virus thymidine kinase gene was used to disrupt 5.5kb of genomic sequence, encoding four exons of the targeted gene. The construct was electroporated into 129S1 derived W9.5 embryonic stem (ES) cells. Correctly targeted ES cells were injected into C57BL/6 blastocysts. The resulting chimeric animals were backcrossed to C57BL/6 mice.

A 32 SNP (single nucleotide polymorphism) panel analysis, with 27 markers covering all 19 chromosomes and the X chromosome, as well as 5 markers that distinguish between the C57BL/6J and C57BL/6N substrains, was performed on the rederived living colony at The Jackson Laboratory Repository. While the 27 markers throughout the genome suggested a C57BL/6 genetic background, 2 of 5 markers that determine C57BL/6J from C57BL/6N were found to be segregating. These data suggest the mice sent to The Jackson Laboratory Repository may have been on a mixed C57BL/6J x C57BL/6N genetic background.

Control Information

  Control
   Wild-type from the colony
   000664 C57BL/6J (approximate)
 
  Considerations for Choosing Controls

Phenotype

Phenotype Information

View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

Mapk8tm1Flv/Mapk8tm1Flv

        B6.129S1-Mapk8tm1Flv
  • integument phenotype
  • abnormal epidermis stratum basale morphology
    • number of proliferating cells in the stratum basale is reduced   (MGI Ref ID J:93433)
  • abnormal keratinocyte differentiation
    • keratohyalin granules, markers of epidermal differentiation, are missing   (MGI Ref ID J:93433)
  • thin epidermis
    • epidermis is thin and consists of fewer cell layers   (MGI Ref ID J:93433)
  • cellular phenotype
  • abnormal keratinocyte differentiation
    • keratohyalin granules, markers of epidermal differentiation, are missing   (MGI Ref ID J:93433)

Mapk8tm1Flv/Mapk8tm1Flv

        B6.129S1-Mapk8tm1Flv/J
  • liver/biliary system phenotype
  • *normal* liver/biliary system phenotype
    • exhibit similar liver injury and mortality from toxin-induced (galactosamine/lipopolysaccharide) liver damage as wild type exhibit similar liver injury and mortality from toxin-induced (galactosamine/lipopolysaccharide) liver damage as wild-type   (MGI Ref ID J:113452)

The following phenotype information is associated with a similar, but not exact match to this JAX® Mice strain.

Mapk8tm1Flv/Mapk8tm1Flv

        involves: 129S1/Sv * C57BL/6
  • cardiovascular system phenotype
  • abnormal myocardium layer morphology
    • after induced ischemia-reperfusion (I-R) injury, mice show significant protection compared to wild-type controls as indicated by reduced viable myocardium area at risk (AAR) versus nonviable infarcted area (IA)   (MGI Ref ID J:102152)
  • decreased cardiomyocyte apoptosis
    • significantly less cleavage of caspase-3 (reduced by about 50%) is observed compared to wild-type   (MGI Ref ID J:102152)
  • muscle phenotype
  • decreased cardiomyocyte apoptosis
    • significantly less cleavage of caspase-3 (reduced by about 50%) is observed compared to wild-type   (MGI Ref ID J:102152)
  • homeostasis/metabolism phenotype
  • abnormal enzyme/coenzyme activity
    • upon UV irradiation, mutant MEFs (mouse embryonic fibroblasts) show an even larger decrease in JNK activity than Mapk9-null MEFs, compared to wild-type   (MGI Ref ID J:112737)
  • cellular phenotype
  • decreased cardiomyocyte apoptosis
    • significantly less cleavage of caspase-3 (reduced by about 50%) is observed compared to wild-type   (MGI Ref ID J:102152)

Mapk8tm1Flv/Mapk8tm1Flv

        involves: 129S1/Sv
  • immune system phenotype
  • abnormal T-helper 1 cell differentiation
    • helper T cells preferentially differentiate to T helper 2 cells, whereas wild-type cells become T helper 1 cells   (MGI Ref ID J:51510)
    • CD4+ T cells are hyperresponsive to anti-CD3 and produce T helper 2 cytokines even in the absence of costimulation   (MGI Ref ID J:51510)
  • abnormal cytokine secretion
    • T helper 2 cells secrete greatly increased amounts of T helper 2 cytokines (10x as much IL-4, 5x as much IL-5, and moderate increase in IL-10), indicating enhanced T helper 2 cell response   (MGI Ref ID J:51510)
  • increased T cell proliferation
    • splenocytes and CD4+ T cells display enhanced proliferation in response to stimulation and CD4+ helper T cells show a moderate reduction of activation-induced cell death   (MGI Ref ID J:51510)
  • hematopoietic system phenotype
  • abnormal T-helper 1 cell differentiation
    • helper T cells preferentially differentiate to T helper 2 cells, whereas wild-type cells become T helper 1 cells   (MGI Ref ID J:51510)
    • CD4+ T cells are hyperresponsive to anti-CD3 and produce T helper 2 cytokines even in the absence of costimulation   (MGI Ref ID J:51510)
  • increased T cell proliferation
    • splenocytes and CD4+ T cells display enhanced proliferation in response to stimulation and CD4+ helper T cells show a moderate reduction of activation-induced cell death   (MGI Ref ID J:51510)
  • tumorigenesis
  • increased incidence of tumors by chemical induction
    • exhibit increased susceptibility to TPA-induced skin tumor development compared to wild-type, with increased rate and number of papillomas   (MGI Ref ID J:75228)
    • exhibit increased incidence and number of TPA-induced carcinomas, indicating that papillomas have an increased risk of undergoing malignant conversion compared to wild-type   (MGI Ref ID J:75228)
  • cardiovascular system phenotype
  • cardiac fibrosis
    • exhibit inflammatory lesions that lead to the development of significant fibrosis following pressure overload compared to wild-type   (MGI Ref ID J:108253)
  • decreased cardiac muscle contractility
    • exhibit a significant reduction in fractional shortening after 3 and 7 days of pressure overload compared to wild-type, however cardiac function improves over time and is similar to wild-type after 12 weeks of TAC   (MGI Ref ID J:108253)
  • increased cardiomyocyte apoptosis
    • exhibit increased rates of myocyte death following pressure overload compared to wild-type   (MGI Ref ID J:108253)
  • increased response of heart to induced stress
    • develop cardiac hypertrophy similar to wild-type after pressure overload, however display a reduction in fractional shortening, increased inflammatory infiltrate and fibrosis and increased myocyte death compared to wild-type   (MGI Ref ID J:108253)
  • muscle phenotype
  • decreased cardiac muscle contractility
    • exhibit a significant reduction in fractional shortening after 3 and 7 days of pressure overload compared to wild-type, however cardiac function improves over time and is similar to wild-type after 12 weeks of TAC   (MGI Ref ID J:108253)
  • increased cardiomyocyte apoptosis
    • exhibit increased rates of myocyte death following pressure overload compared to wild-type   (MGI Ref ID J:108253)
  • homeostasis/metabolism phenotype
  • cardiac fibrosis
    • exhibit inflammatory lesions that lead to the development of significant fibrosis following pressure overload compared to wild-type   (MGI Ref ID J:108253)
  • increased incidence of tumors by chemical induction
    • exhibit increased susceptibility to TPA-induced skin tumor development compared to wild-type, with increased rate and number of papillomas   (MGI Ref ID J:75228)
    • exhibit increased incidence and number of TPA-induced carcinomas, indicating that papillomas have an increased risk of undergoing malignant conversion compared to wild-type   (MGI Ref ID J:75228)
  • increased response of heart to induced stress
    • develop cardiac hypertrophy similar to wild-type after pressure overload, however display a reduction in fractional shortening, increased inflammatory infiltrate and fibrosis and increased myocyte death compared to wild-type   (MGI Ref ID J:108253)
  • cellular phenotype
  • increased cardiomyocyte apoptosis
    • exhibit increased rates of myocyte death following pressure overload compared to wild-type   (MGI Ref ID J:108253)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Mapk8tm1Flv related

Immunology, Inflammation and Autoimmunity Research
Intracellular Signaling Molecules

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Mapk8tm1Flv
Allele Name targeted mutation 1, Richard Flavell
Allele Type Targeted (Null/Knockout)
Common Name(s) Jnk1 -; Jnk1 KO;
Mutation Made ByDr. Richard Flavell,   Yale University School of Medicine
Strain of Origin129S1/Sv-Oca2<+> Tyr<+> Kitl<+>
ES Cell Line NameW9.5/W95
ES Cell Line Strain129S1/Sv-Oca2<+> Tyr<+> Kitl<+>
Gene Symbol and Name Mapk8, mitogen-activated protein kinase 8
Chromosome 14
Gene Common Name(s) AI849689; JNK; JNK-46; JNK1; JNK1A2; JNK21B1/2; PRKM8; Prkm8; SAPK1; SAPK1c; c-Jun N-terminal kinase; expressed sequence AI849689; protein kinase mitogen-activated 8;
Molecular Note A hygromycin resistance cassette replaced a 5.5 kb genomic fragment containing four exons of the gene. Western blot analysis on extracts derived from embryonic fibroblasts of homozygous mice confirmed that no detectable protein was expressed from this allele. [MGI Ref ID J:51510]

Genotyping

Genotyping Information

Genotyping Protocols

Mapk8tm1 Flv/J MCA SEP, Melt Curve Analysis
Mapk8tm1Flv, Standard PCR


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Dong C; Yang DD; Wysk M; Whitmarsh AJ; Davis RJ; Flavell RA. 1998. Defective T cell differentiation in the absence of Jnk1. Science 282(5396):2092-5. [PubMed: 9851932]  [MGI Ref ID J:51510]

Additional References

Constant SL; Dong C; Yang DD; Wysk M; Davis RJ; Flavell RA. 2000. JNK1 is required for T cell-mediated immunity against Leishmania major infection. J Immunol 165(5):2671-6. [PubMed: 10946297]  [MGI Ref ID J:64050]

Mapk8tm1Flv related

Abdelli S; Puyal J; Bielmann C; Buchillier V; Abderrahmani A; Clarke PG; Beckmann JS; Bonny C. 2009. JNK3 is abundant in insulin-secreting cells and protects against cytokine-induced apoptosis. Diabetologia 52(9):1871-80. [PubMed: 19609503]  [MGI Ref ID J:154878]

Adam F; Kauskot A; Nurden P; Sulpice E; Hoylaerts MF; Davis RJ; Rosa JP; Bryckaert M. 2010. Platelet JNK1 is involved in secretion and thrombus formation. Blood 115(20):4083-92. [PubMed: 20231429]  [MGI Ref ID J:160229]

Adhikary G; Sun Y; Pearlman E. 2008. C-Jun NH2 terminal kinase (JNK) is an essential mediator of Toll-like receptor 2-induced corneal inflammation. J Leukoc Biol 83(4):991-7. [PubMed: 18218857]  [MGI Ref ID J:134160]

Alcorn JF; Guala AS; van der Velden J; McElhinney B; Irvin CG; Davis RJ; Janssen-Heininger YM. 2008. Jun N-terminal kinase 1 regulates epithelial-to-mesenchymal transition induced by TGF-beta1. J Cell Sci 121(Pt 7):1036-45. [PubMed: 18334556]  [MGI Ref ID J:138475]

Alcorn JF; van der Velden J; Brown AL; McElhinney B; Irvin CG; Janssen-Heininger YM. 2009. c-Jun N-terminal kinase 1 is required for the development of pulmonary fibrosis. Am J Respir Cell Mol Biol 40(4):422-32. [PubMed: 18836136]  [MGI Ref ID J:159273]

Anbalagan M; Sabapathy K. 2012. JNK1 and JNK2 play redundant functions in Myc-induced B cell lymphoma formation. Int J Cancer 130(8):1967-9. [PubMed: 21630260]  [MGI Ref ID J:181076]

Barnat M; Enslen H; Propst F; Davis RJ; Soares S; Nothias F. 2010. Distinct roles of c-Jun N-terminal kinase isoforms in neurite initiation and elongation during axonal regeneration. J Neurosci 30(23):7804-16. [PubMed: 20534829]  [MGI Ref ID J:160890]

Bjorkblom B; Ostman N; Hongisto V; Komarovski V; Filen JJ; Nyman TA; Kallunki T; Courtney MJ; Coffey ET. 2005. Constitutively active cytoplasmic c-Jun N-terminal kinase 1 is a dominant regulator of dendritic architecture: role of microtubule-associated protein 2 as an effector. J Neurosci 25(27):6350-61. [PubMed: 16000625]  [MGI Ref ID J:99429]

Bonnesen B; Orskov C; Rasmussen S; Holst PJ; Christensen JP; Eriksen KW; Qvortrup K; Odum N; Labuda T. 2005. MEK kinase 1 activity is required for definitive erythropoiesis in the mouse fetal liver. Blood 106(10):3396-404. [PubMed: 16081685]  [MGI Ref ID J:124072]

Bourdi M; Korrapati MC; Chakraborty M; Yee SB; Pohl LR. 2008. Protective role of c-Jun N-terminal kinase 2 in acetaminophen-induced liver injury. Biochem Biophys Res Commun 374(1):6-10. [PubMed: 18586006]  [MGI Ref ID J:139164]

Brecht S; Kirchhof R; Chromik A; Willesen M; Nicolaus T; Raivich G; Wessig J; Waetzig V; Goetz M; Claussen M; Pearse D; Kuan CY; Vaudano E; Behrens A; Wagner E; Flavell RA; Davis RJ; Herdegen T. 2005. Specific pathophysiological functions of JNK isoforms in the brain. Eur J Neurosci 21(2):363-77. [PubMed: 15673436]  [MGI Ref ID J:100808]

Casals-Casas C; Alvarez E; Serra M; de la Torre C; Farrera C; Sanchez-Tillo E; Caelles C; Lloberas J; Celada A. 2009. CREB and AP-1 activation regulates MKP-1 induction by LPS or M-CSF and their kinetics correlate with macrophage activation versus proliferation. Eur J Immunol 39(7):1902-1913. [PubMed: 19585511]  [MGI Ref ID J:150260]

Cellurale C; Sabio G; Kennedy NJ; Das M; Barlow M; Sandy P; Jacks T; Davis RJ. 2011. Requirement of c-Jun NH2-Terminal Kinase for Ras-Initiated Tumor Formation. Mol Cell Biol 31(7):1565-76. [PubMed: 21282468]  [MGI Ref ID J:170101]

Cellurale C; Weston CR; Reilly J; Garlick DS; Jerry DJ; Sluss HK; Davis RJ. 2010. Role of JNK in a Trp53-dependent mouse model of breast cancer. PLoS One 5(8):. [PubMed: 20814571]  [MGI Ref ID J:163993]

Chaudhury H; Zakkar M; Boyle J; Cuhlmann S; van der Heiden K; Luong le A; Davis J; Platt A; Mason JC; Krams R; Haskard DO; Clark AR; Evans PC. 2010. c-Jun N-terminal kinase primes endothelial cells at atheroprone sites for apoptosis. Arterioscler Thromb Vasc Biol 30(3):546-53. [PubMed: 20056910]  [MGI Ref ID J:172150]

Choi HS; Bode AM; Shim JH; Lee SY; Dong Z. 2009. c-Jun N-terminal kinase 1 phosphorylates Myt1 to prevent UVA-induced skin cancer. Mol Cell Biol 29(8):2168-80. [PubMed: 19204086]  [MGI Ref ID J:147767]

Choi J; Kim JR; Kim H; Kim YA; Lee HJ; Kim J; Lee KW. 2013. The atopic dermatitis-like symptoms induced by MC903 were alleviated in JNK1 knockout mice. Toxicol Sci 136(2):443-9. [PubMed: 24046278]  [MGI Ref ID J:207545]

Chromik AM; Muller AM; Korner J; Belyaev O; Holland-Letz T; Schmitz F; Herdegen T; Uhl W; Mittelkotter U. 2007. Genetic deletion of JNK1 and JNK2 aggravates the DSS-induced colitis in mice. J Invest Surg 20(1):23-33. [PubMed: 17365404]  [MGI Ref ID J:130576]

Constant SL; Dong C; Yang DD; Wysk M; Davis RJ; Flavell RA. 2000. JNK1 is required for T cell-mediated immunity against Leishmania major infection. J Immunol 165(5):2671-6. [PubMed: 10946297]  [MGI Ref ID J:64050]

Conze D; Krahl T; Kennedy N; Weiss L; Lumsden J; Hess P; Flavell RA; Le Gros G; Davis RJ; Rincon M. 2002. c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 have distinct roles in CD8(+) T cell activation. J Exp Med 195(7):811-23. [PubMed: 11927626]  [MGI Ref ID J:124416]

Das M; Sabio G; Jiang F; Rincon M; Flavell RA; Davis RJ. 2009. Induction of hepatitis by JNK-mediated expression of TNF-alpha. Cell 136(2):249-60. [PubMed: 19167327]  [MGI Ref ID J:147632]

Denninger K; Rasmussen S; Larsen JM; Orskov C; Seier Poulsen S; Sorensen P; Christensen JP; Illges H; Odum N; Labuda T. 2011. JNK1, but Not JNK2, Is Required in Two Mechanistically Distinct Models of Inflammatory Arthritis. Am J Pathol 179(4):1884-93. [PubMed: 21839715]  [MGI Ref ID J:176299]

Diaz-Delfin J; Hondares E; Iglesias R; Giralt M; Caelles C; Villarroya F. 2012. TNF-alpha represses beta-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology 153(9):4238-45. [PubMed: 22778214]  [MGI Ref ID J:189171]

Diaz-Delfin J; Morales M; Caelles C. 2007. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway. Diabetes 56(7):1865-71. [PubMed: 17416798]  [MGI Ref ID J:126454]

Dolinay T; Wu W; Kaminski N; Ifedigbo E; Kaynar AM; Szilasi M; Watkins SC; Ryter SW; Hoetzel A; Choi AM. 2008. Mitogen-activated protein kinases regulate susceptibility to ventilator-induced lung injury. PLoS ONE 3(2):e1601. [PubMed: 18270588]  [MGI Ref ID J:132187]

Dong C; Yang DD; Tournier C; Whitmarsh AJ; Xu J; Davis RJ; Flavell RA. 2000. JNK is required for effector T-cell function but not for T-cell activation. Nature 405(6782):91-4. [PubMed: 10811224]  [MGI Ref ID J:61895]

Fujii N; Boppart MD; Dufresne SD; Crowley PF; Jozsi AC; Sakamoto K; Yu H; Aschenbach WG; Kim S; Miyazaki H; Rui L; White MF; Hirshman MF; Goodyear LJ. 2004. Overexpression or ablation of JNK in skeletal muscle has no effect on glycogen synthase activity. Am J Physiol Cell Physiol 287(1):C200-8. [PubMed: 15013949]  [MGI Ref ID J:95346]

Fukuda K; Tesch GH; Nikolic-Paterson DJ. 2008. c-Jun amino terminal kinase 1 deficient mice are protected from streptozotocin-induced islet injury. Biochem Biophys Res Commun 366(3):710-6. [PubMed: 18082135]  [MGI Ref ID J:130705]

Gao Y; Tao J; Li MO; Zhang D; Chi H; Henegariu O; Kaech SM; Davis RJ; Flavell RA; Yin Z. 2005. JNK1 is essential for CD8+ T cell-mediated tumor immune surveillance. J Immunol 175(9):5783-9. [PubMed: 16237070]  [MGI Ref ID J:119340]

Gao Z; Zhang J; Kheterpal I; Kennedy N; Davis RJ; Ye J. 2011. Sirtuin 1 (SIRT1) protein degradation in response to persistent c-Jun N-terminal kinase 1 (JNK1) activation contributes to hepatic steatosis in obesity. J Biol Chem 286(25):22227-34. [PubMed: 21540183]  [MGI Ref ID J:174806]

Heinonen KM; Vanegas JR; Lew D; Krosl J; Perreault C. 2011. Wnt4 enhances murine hematopoietic progenitor cell expansion through a planar cell polarity-like pathway. PLoS One 6(4):e19279. [PubMed: 21541287]  [MGI Ref ID J:172379]

Hess P; Pihan G; Sawyers CL; Flavell RA; Davis RJ. 2002. Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts. Nat Genet 32(1):201-5. [PubMed: 12161751]  [MGI Ref ID J:92945]

Hirai S; Banba Y; Satake T; Ohno S. 2011. Axon Formation in Neocortical Neurons Depends on Stage-Specific Regulation of Microtubule Stability by the Dual Leucine Zipper Kinase-c-Jun N-Terminal Kinase Pathway. J Neurosci 31(17):6468-80. [PubMed: 21525288]  [MGI Ref ID J:171420]

Hu D; Fang W; Han A; Gallagher L; Davis RJ; Xiong B; Yang W. 2008. c-Jun N-terminal kinase 1 interacts with and negatively regulates Wnt/beta-catenin signaling through GSK3beta pathway. Carcinogenesis 29(12):2317-24. [PubMed: 18952597]  [MGI Ref ID J:144866]

Hubner A; Barrett T; Flavell RA; Davis RJ. 2008. Multisite phosphorylation regulates Bim stability and apoptotic activity. Mol Cell 30(4):415-25. [PubMed: 18498746]  [MGI Ref ID J:137061]

Hubner A; Mulholland DJ; Standen CL; Karasarides M; Cavanagh-Kyros J; Barrett T; Chi H; Greiner DL; Tournier C; Sawyers CL; Flavell RA; Wu H; Davis RJ. 2012. JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proc Natl Acad Sci U S A 109(30):12046-51. [PubMed: 22753496]  [MGI Ref ID J:186492]

Hunot S; Vila M; Teismann P; Davis RJ; Hirsch EC; Przedborski S; Rakic P; Flavell RA. 2004. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 101(2):665-70. [PubMed: 14704277]  [MGI Ref ID J:87428]

Ijaz A; Tejada T; Catanuto P; Xia X; Elliot SJ; Lenz O; Jauregui A; Saenz MO; Molano RD; Pileggi A; Ricordi C; Fornoni A. 2009. Inhibition of C-jun N-terminal kinase improves insulin sensitivity but worsens albuminuria in experimental diabetes. Kidney Int 75(4):381-8. [PubMed: 18971923]  [MGI Ref ID J:162711]

Jaeschke A; Karasarides M; Ventura JJ; Ehrhardt A; Zhang C; Flavell RA; Shokat KM; Davis RJ. 2006. JNK2 is a positive regulator of the cJun transcription factor. Mol Cell 23(6):899-911. [PubMed: 16973441]  [MGI Ref ID J:112737]

Junyent F; de Lemos L; Verdaguer E; Folch J; Ferrer I; Ortuno-Sahagun D; Beas-Zarate C; Romero R; Pallas M; Auladell C; Camins A. 2011. Gene expression profile in JNK3 null mice: a novel specific activation of the PI3K/AKT pathway. J Neurochem 117(2):244-252. [PubMed: 21255018]  [MGI Ref ID J:171529]

Kaiser RA; Liang Q; Bueno O; Huang Y; Lackey T; Klevitsky R; Hewett TE; Molkentin JD. 2005. Genetic inhibition or activation of JNK1/2 protects the myocardium from ischemia-reperfusion-induced cell death in vivo. J Biol Chem 280(38):32602-8. [PubMed: 16043490]  [MGI Ref ID J:102152]

Kelkar N; Delmotte MH; Weston CR; Barrett T; Sheppard BJ; Flavell RA; Davis RJ. 2003. Morphogenesis of the telencephalic commissure requires scaffold protein JNK-interacting protein 3 (JIP3). Proc Natl Acad Sci U S A 100(17):9843-8. [PubMed: 12897243]  [MGI Ref ID J:85160]

Keramaris E; Vanderluit JL; Bahadori M; Mousavi K; Davis RJ; Flavell R; Slack RS; Park DS. 2005. c-Jun N-terminal kinase 3 deficiency protects neurons from axotomy-induced death in vivo through mechanisms independent of c-Jun phosphorylation. J Biol Chem 280(2):1132-41. [PubMed: 15528206]  [MGI Ref ID J:96192]

Kim HP; Wang X; Zhang J; Suh GY; Benjamin IJ; Ryter SW; Choi AM. 2005. Heat shock protein-70 mediates the cytoprotective effect of carbon monoxide: involvement of p38 beta MAPK and heat shock factor-1. J Immunol 175(4):2622-9. [PubMed: 16081837]  [MGI Ref ID J:107488]

Kodama Y; Taura K; Miura K; Schnabl B; Osawa Y; Brenner DA. 2009. Antiapoptotic effect of c-Jun N-terminal Kinase-1 through Mcl-1 stabilization in TNF-induced hepatocyte apoptosis. Gastroenterology 136(4):1423-34. [PubMed: 19249395]  [MGI Ref ID J:148191]

Kuan CY; Whitmarsh AJ; Yang DD; Liao G; Schloemer AJ; Dong C; Bao J; Banasiak KJ; Haddad GG; Flavell RA; Davis RJ; Rakic P. 2003. A critical role of neural-specific JNK3 for ischemic apoptosis. Proc Natl Acad Sci U S A 100(25):15184-9. [PubMed: 14657393]  [MGI Ref ID J:86985]

Kuan CY; Yang DD; Samanta Roy DR; Davis RJ; Rakic P; Flavell RA. 1999. The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron 22(4):667-76. [PubMed: 10230788]  [MGI Ref ID J:54653]

Li X; Weng H; Xu C; Reece EA; Yang P. 2012. Oxidative stress-induced JNK1/2 activation triggers proapoptotic signaling and apoptosis that leads to diabetic embryopathy. Diabetes 61(8):2084-92. [PubMed: 22688338]  [MGI Ref ID J:208533]

Li X; Xu C; Yang P. 2013. c-Jun NH2-terminal kinase 1/2 and endoplasmic reticulum stress as interdependent and reciprocal causation in diabetic embryopathy. Diabetes 62(2):599-608. [PubMed: 22961085]  [MGI Ref ID J:208480]

Liang Q; Bueno OF; Wilkins BJ; Kuan CY; Xia Y; Molkentin JD. 2003. c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling. EMBO J 22(19):5079-89. [PubMed: 14517246]  [MGI Ref ID J:85947]

Melief EJ; Miyatake M; Bruchas MR; Chavkin C. 2010. Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling. Proc Natl Acad Sci U S A 107(25):11608-13. [PubMed: 20534436]  [MGI Ref ID J:161284]

Morse D; Otterbein LE; Watkins S; Alber S; Zhou Z; Flavell RA; Davis RJ; Choi AM. 2003. Deficiency in the c-Jun NH2-terminal kinase signaling pathway confers susceptibility to hyperoxic lung injury in mice. Am J Physiol Lung Cell Mol Physiol 285(1):L250-7. [PubMed: 12651633]  [MGI Ref ID J:84268]

Nagelin MH; Srinivasan S; Nadler JL; Hedrick CC. 2009. Murine 12/15-lipoxygenase regulates ATP-binding cassette transporter G1 protein degradation through p38- and JNK2-dependent pathways. J Biol Chem 284(45):31303-14. [PubMed: 19713213]  [MGI Ref ID J:156345]

Ni HM; Chen X; Ding WX; Schuchmann M; Yin XM. 2008. Differential roles of JNK in ConA/GalN and ConA-induced liver injury in mice. Am J Pathol 173(4):962-72. [PubMed: 18772342]  [MGI Ref ID J:139659]

Ni HM; Chen X; Shi YH; Liao Y; Beg AA; Fan J; Yin XM. 2009. Genetic delineation of the pathways mediated by bid and JNK in tumor necrosis factor-alpha-induced liver injury in adult and embryonic mice. J Biol Chem 284(7):4373-82. [PubMed: 19060338]  [MGI Ref ID J:147600]

Peck-Palmer OM; Unsinger J; Chang KC; Davis CG; McDunn JE; Hotchkiss RS. 2008. Deletion of MyD88 markedly attenuates sepsis-induced T and B lymphocyte apoptosis but worsens survival. J Leukoc Biol 83(4):1009-18. [PubMed: 18211965]  [MGI Ref ID J:134048]

Reinecke K; Herdegen T; Eminel S; Aldenhoff JB; Schiffelholz T. 2013. Knockout of c-Jun N-terminal kinases 1, 2 or 3 isoforms induces behavioural changes. Behav Brain Res 245:88-95. [PubMed: 23428746]  [MGI Ref ID J:197459]

Ricci R; Sumara G; Sumara I; Rozenberg I; Kurrer M; Akhmedov A; Hersberger M; Eriksson U; Eberli FR; Becher B; Boren J; Chen M; Cybulsky MI; Moore KJ; Freeman MW; Wagner EF; Matter CM; Luscher TF. 2004. Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. Science 306(5701):1558-61. [PubMed: 15567863]  [MGI Ref ID J:94044]

Roberson EC; Tully JE; Guala AS; Reiss JN; Godburn KE; Pociask DA; Alcorn JF; Riches DW; Dienz O; Janssen-Heininger YM; Anathy V. 2012. Influenza induces endoplasmic reticulum stress, caspase-12-dependent apoptosis, and c-Jun N-terminal kinase-mediated transforming growth factor-beta release in lung epithelial cells. Am J Respir Cell Mol Biol 46(5):573-81. [PubMed: 21799120]  [MGI Ref ID J:196041]

Ruff CA; Staak N; Patodia S; Kaswich M; Rocha-Ferreira E; Da Costa C; Brecht S; Makwana M; Fontana X; Hristova M; Rumajogee P; Galiano M; Bohatschek M; Herdegen T; Behrens A; Raivich G. 2012. Neuronal c-Jun is required for successful axonal regeneration, but the effects of phosphorylation of its N-terminus are moderate. J Neurochem 121(4):607-18. [PubMed: 22372722]  [MGI Ref ID J:184366]

Sabio G; Cavanagh-Kyros J; Barrett T; Jung DY; Ko HJ; Ong H; Morel C; Mora A; Reilly J; Kim JK; Davis RJ. 2010. Role of the hypothalamic-pituitary-thyroid axis in metabolic regulation by JNK1. Genes Dev 24(3):256-64. [PubMed: 20080940]  [MGI Ref ID J:156939]

Sabio G; Cavanagh-Kyros J; Ko HJ; Jung DY; Gray S; Jun JY; Barrett T; Mora A; Kim JK; Davis RJ. 2009. Prevention of steatosis by hepatic JNK1. Cell Metab 10(6):491-8. [PubMed: 19945406]  [MGI Ref ID J:155978]

Sabio G; Das M; Mora A; Zhang Z; Jun JY; Ko HJ; Barrett T; Kim JK; Davis RJ. 2008. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 322(5907):1539-43. [PubMed: 19056984]  [MGI Ref ID J:142035]

Sabio G; Kennedy NJ; Cavanagh-Kyros J; Jung DY; Ko HJ; Ong H; Barrett T; Kim JK; Davis RJ. 2010. Role of muscle c-Jun NH2-terminal kinase 1 in obesity-induced insulin resistance. Mol Cell Biol 30(1):106-15. [PubMed: 19841069]  [MGI Ref ID J:156374]

Samak G; Suzuki T; Bhargava A; Rao RK. 2010. c-Jun NH2-terminal kinase-2 mediates osmotic stress-induced tight junction disruption in the intestinal epithelium. Am J Physiol Gastrointest Liver Physiol 299(3):G572-84. [PubMed: 20595622]  [MGI Ref ID J:163330]

Sanchez-Tillo E; Comalada M; Xaus J; Farrera C; Valledor AF; Caelles C; Lloberas J; Celada A. 2007. JNK1 Is required for the induction of Mkp1 expression in macrophages during proliferation and lipopolysaccharide-dependent activation. J Biol Chem 282(17):12566-73. [PubMed: 17337450]  [MGI Ref ID J:121267]

She QB; Chen N; Bode AM; Flavell RA; Dong Z. 2002. Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 62(5):1343-8. [PubMed: 11888903]  [MGI Ref ID J:75228]

Sherrin T; Blank T; Hippel C; Rayner M; Davis RJ; Todorovic C. 2010. Hippocampal c-Jun-N-terminal kinases serve as negative regulators of associative learning. J Neurosci 30(40):13348-61. [PubMed: 20926661]  [MGI Ref ID J:165097]

Tachibana H; Perrino C; Takaoka H; Davis RJ; Naga Prasad SV; Rockman HA. 2006. JNK1 is required to preserve cardiac function in the early response to pressure overload. Biochem Biophys Res Commun 343(4):1060-6. [PubMed: 16579967]  [MGI Ref ID J:108253]

Tong C; Yin Z; Song Z; Dockendorff A; Huang C; Mariadason J; Flavell RA; Davis RJ; Augenlicht LH; Yang W. 2007. c-Jun NH2-terminal kinase 1 plays a critical role in intestinal homeostasis and tumor suppression. Am J Pathol 171(1):297-303. [PubMed: 17591974]  [MGI Ref ID J:122824]

Tortoriello G; Morris CV; Alpar A; Fuzik J; Shirran SL; Calvigioni D; Keimpema E; Botting CH; Reinecke K; Herdegen T; Courtney M; Hurd YL; Harkany T. 2014. Miswiring the brain: Delta9-tetrahydrocannabinol disrupts cortical development by inducing an SCG10/stathmin-2 degradation pathway. EMBO J 33(7):668-85. [PubMed: 24469251]  [MGI Ref ID J:208048]

Tournier C; Hess P; Yang DD; Xu J; Turner TK; Nimnual A; Bar-Sagi D; Jones SN; Flavell RA; Davis RJ. 2000. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 288(5467):870-4. [PubMed: 10797012]  [MGI Ref ID J:137332]

Tran EH; Azuma YT; Chen M; Weston C; Davis RJ; Flavell RA. 2006. Inactivation of JNK1 enhances innate IL-10 production and dampens autoimmune inflammation in the brain. Proc Natl Acad Sci U S A 103(36):13451-6. [PubMed: 16938889]  [MGI Ref ID J:112902]

Unger EK; Piper ML; Olofsson LE; Xu AW. 2010. Functional role of c-Jun-N-terminal kinase in feeding regulation. Endocrinology 151(2):671-82. [PubMed: 20022934]  [MGI Ref ID J:168180]

Valledor AF; Arpa L; Sanchez-Tillo E; Comalada M; Casals C; Xaus J; Caelles C; Lloberas J; Celada A. 2008. IFN-{gamma}-mediated inhibition of MAPK phosphatase expression results in prolonged MAPK activity in response to M-CSF and inhibition of proliferation. Blood 112(8):3274-82. [PubMed: 18682602]  [MGI Ref ID J:140209]

Valledor AF; Sanchez-Tillo E; Arpa L; Park JM; Caelles C; Lloberas J; Celada A. 2008. Selective Roles of MAPKs during the Macrophage Response to IFN-{gamma}. J Immunol 180(7):4523-9. [PubMed: 18354174]  [MGI Ref ID J:132992]

Van der Velden J; Janssen-Heininger YM; Mandalapu S; Scheller EV; Kolls JK; Alcorn JF. 2012. Differential requirement for c-Jun N-terminal kinase 1 in lung inflammation and host defense. PLoS One 7(4):e34638. [PubMed: 22514650]  [MGI Ref ID J:187081]

Vandevyver S; Dejager L; Van Bogaert T; Kleyman A; Liu Y; Tuckermann J; Libert C. 2012. Glucocorticoid receptor dimerization induces MKP1 to protect against TNF-induced inflammation. J Clin Invest 122(6):2130-40. [PubMed: 22585571]  [MGI Ref ID J:190494]

Varona-Santos JL; Pileggi A; Molano RD; Sanabria NY; Ijaz A; Atsushi M; Ichii H; Pastori RL; Inverardi L; Ricordi C; Fornoni A. 2008. c-Jun N-terminal kinase 1 is deleterious to the function and survival of murine pancreatic islets. Diabetologia 51(12):2271-80. [PubMed: 18853132]  [MGI Ref ID J:141417]

Wang S; Villablanca EJ; De Calisto J; Gomes DC; Nguyen DD; Mizoguchi E; Kagan JC; Reinecker HC; Hacohen N; Nagler C; Xavier RJ; Rossi-Bergmann B; Chen YB; Blomhoff R; Snapper SB; Mora JR. 2011. MyD88-dependent TLR1/2 signals educate dendritic cells with gut-specific imprinting properties. J Immunol 187(1):141-50. [PubMed: 21646294]  [MGI Ref ID J:176180]

Wang Y; Singh R; Lefkowitch JH; Rigoli RM; Czaja MJ. 2006. Tumor necrosis factor-induced toxic liver injury results from JNK2-dependent activation of caspase-8 and the mitochondrial death pathway. J Biol Chem 281(22):15258-67. [PubMed: 16571730]  [MGI Ref ID J:113452]

Westerlund N; Zdrojewska J; Padzik A; Komulainen E; Bjorkblom B; Rannikko E; Tararuk T; Garcia-Frigola C; Sandholm J; Nguyen L; Kallunki T; Courtney MJ; Coffey ET. 2011. Phosphorylation of SCG10/stathmin-2 determines multipolar stage exit and neuronal migration rate. Nat Neurosci 14(3):305-13. [PubMed: 21297631]  [MGI Ref ID J:170348]

Weston CR; Wong A; Hall JP; Goad ME; Flavell RA; Davis RJ. 2003. JNK initiates a cytokine cascade that causes Pax2 expression and closure of the optic fissure. Genes Dev 17(10):1271-80. [PubMed: 12756228]  [MGI Ref ID J:83385]

Weston CR; Wong A; Hall JP; Goad ME; Flavell RA; Davis RJ. 2004. The c-Jun NH2-terminal kinase is essential for epidermal growth factor expression during epidermal morphogenesis. Proc Natl Acad Sci U S A 101(39):14114-9. [PubMed: 15375216]  [MGI Ref ID J:93433]

Wu HJ; Venkataraman C; Estus S; Dong C; Davis RJ; Flavell RA; Bondada S. 2001. Positive signaling through CD72 induces mitogen-activated protein kinase activation and synergizes with B cell receptor signals to induce X-linked immunodeficiency B cell proliferation. J Immunol 167(3):1263-73. [PubMed: 11466342]  [MGI Ref ID J:120492]

Xu P; Das M; Reilly J; Davis RJ. 2011. JNK regulates FoxO-dependent autophagy in neurons. Genes Dev 25(4):310-22. [PubMed: 21325132]  [MGI Ref ID J:169060]

Xu P; Davis RJ. 2010. c-Jun NH2-terminal kinase is required for lineage-specific differentiation but not stem cell self-renewal. Mol Cell Biol 30(6):1329-40. [PubMed: 20065035]  [MGI Ref ID J:161736]

Yang L; Wu D; Wang X; Cederbaum AI. 2012. Cytochrome P4502E1, oxidative stress, JNK, and autophagy in acute alcohol-induced fatty liver. Free Radic Biol Med 53(5):1170-80. [PubMed: 22749809]  [MGI Ref ID J:188051]

Yoshimura K; Ueno M; Lee S; Nakamura Y; Sato A; Yoshimura K; Kishima H; Yoshimine T; Yamashita T. 2011. C-Jun N-terminal kinase induces axonal degeneration and limits motor recovery after spinal cord injury in mice. Neurosci Res 71(3):266-77. [PubMed: 21824499]  [MGI Ref ID J:180900]

Zhang L; Huang X; Meng Z; Dong B; Shiah S; Moore DD; Huang W. 2009. Significance and Mechanism of CYP7a1 Gene Regulation during the Acute Phase of Liver Regeneration. Mol Endocrinol 23(2):137-45. [PubMed: 19056864]  [MGI Ref ID J:144235]

Zhang T; Lu X; Arnold P; Liu Y; Baliga R; Huang H; Bauer JA; Liu Y; Feng Q. 2012. Mitogen-activated protein kinase phosphatase-1 inhibits myocardial TNF-alpha expression and improves cardiac function during endotoxemia. Cardiovasc Res 93(3):471-9. [PubMed: 22198506]  [MGI Ref ID J:194710]

van der Velden JL; Hoffman SM; Alcorn JF; Tully JE; Chapman DG; Lahue KG; Guala AS; Lundblad LK; Aliyeva M; Daphtary N; Irvin CG; Janssen-Heininger YM. 2014. Absence of c-Jun NH2-terminal kinase 1 protects against house dust mite-induced pulmonary remodeling but not airway hyperresponsiveness and inflammation. Am J Physiol Lung Cell Mol Physiol 306(9):L866-75. [PubMed: 24610935]  [MGI Ref ID J:210991]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Room Number           AX11

Colony Maintenance

Breeding & HusbandryThis strain originated on a B6;129S1 background and has been backcrossed for 5 generations on the C57BL/6 background. This strain is maintained by heterozygous crosses, due to poor breeding performance of homozygous mice. Coat color expected from breeding:Black
Mating SystemHeterozygote x Heterozygote         (Female x Male)   01-MAR-06
Diet Information LabDiet® 5K52/5K67

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Live Mice

Price per mouse (US dollars $)GenderGenotypes Provided
Individual Mouse $239.00Female or MaleHeterozygous for Mapk8tm1Flv  
$239.00Female or MaleHomozygous for Mapk8tm1Flv  
Price per Pair (US dollars $)Pair Genotype
$478.00Heterozygous for Mapk8tm1Flv x Heterozygous for Mapk8tm1Flv  

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Live Mice

Price per mouse (US dollars $)GenderGenotypes Provided
Individual Mouse $310.70Female or MaleHeterozygous for Mapk8tm1Flv  
$310.70Female or MaleHomozygous for Mapk8tm1Flv  
Price per Pair (US dollars $)Pair Genotype
$621.40Heterozygous for Mapk8tm1Flv x Heterozygous for Mapk8tm1Flv  

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

Control Information

  Control
   Wild-type from the colony
   000664 C57BL/6J (approximate)
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.

Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.8)